This renewal application addresses the questions raised by the results obtained in the present period. It focuses on the regression and progression phases that the DMBA induced skin tumors in rabbits present. In the results obtained so far we have found H-ras to be activated in benign and self-regressing tumors (keratoacanthomas, K.A.s) at a significantly lower frequency than in squamous cell carcinomas (SCCs). This is occurring in humans and rabbits. The mutant H-ras allele is expressed during the mature and regressing phases of the KA. We will now test the hypothesis that H-ras is involved in the KA regression by analyzing an array of in vitro and in vivo systems. We will use transient expression assays in rabbit corneal epithelial cells, stable expression in cell cultures and long term phenotypic experiments in transgenic rabbits injected with several ras constructions under the control of an inducible keratin promoter. This will be combined with the study of the TGF beta 1, 2, and 3 expression in this system, their possible induction by ras oncogenes and its correlation with differentiation in this system. Complementary, and based on our preliminary results, we will study other genes that could be involved in the process of progression to SCC. To that effect we will complete the cloning of a dominant oncogene detected in a rabbit SCC and we will analyze its molecular structure and role in skin tumors progression.. The molecular characterization of this unique system that displays both regression and progression should be very instrumental in dissecting the tumorigenesis process and the role of ras in it.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA050434-04
Application #
3194898
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1989-08-01
Project End
1997-07-31
Budget Start
1992-08-01
Budget End
1993-07-31
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Osei-Sarfo, Kwame; de Castro, Ignacio Perez; Pellicer, Angel (2012) p15(INK4b) plays a crucial role in murine lymphoid development and tumorigenesis. Carcinogenesis 33:708-13
Suzme, R; Tseng, J-C; Levin, B et al. (2012) Sindbis viral vectors target hematopoietic malignant cells. Cancer Gene Ther 19:757-66
Osei-Sarfo, K; Martello, L; Ibrahim, S et al. (2011) The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral. Oncogene 30:3661-71
Martello, Laura A; Pellicer, Angel (2006) Biochemical and biological analyses of Rgr RalGEF oncogene. Methods Enzymol 407:115-28
Jimenez, Maria; Perez de Castro, Ignacio; Benet, Marta et al. (2004) The Rgr oncogene induces tumorigenesis in transgenic mice. Cancer Res 64:6041-9
Perez de Castro, Ignacio; Bivona, Trever G; Philips, Mark R et al. (2004) Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol 24:3485-96
Hernandez-Munoz, Inmaculada; Benet, Marta; Calero, Miguel et al. (2003) rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res 63:4188-95
Leonardi, Peter; Kassin, Ezra; Hernandez-Munoz, Inmaculada et al. (2002) Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene 21:5108-16
Zagzag, D; Miller, D C; Knopp, E et al. (2000) Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics 106:1045-53
Hernandez-Munoz, I; Malumbres, M; Leonardi, P et al. (2000) The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways. Oncogene 19:2745-57

Showing the most recent 10 out of 40 publications